166 related articles for article (PubMed ID: 19069139)
1. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction].
Hosoya T; Okada H; Horio M; Ohno I; Tamura S; Sugimoto H; Tsushima Y; Hayashi H; Fukuda K
Nihon Jinzo Gakkai Shi; 2008; 50(7):858-60. PubMed ID: 19069139
[No Abstract] [Full Text] [Related]
2. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].
Hosoya T; Okada H; Horio M; Ohno I; Tamura S; Sugimoto H; Tsushima Y; Hayashi H; Fukuda K; Korogi Y; Yoshifumi N
Nihon Jinzo Gakkai Shi; 2009; 51(7):839-42. PubMed ID: 19928554
[No Abstract] [Full Text] [Related]
3. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
5. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
6. NSF: still relevant.
Thomsen HS
J Magn Reson Imaging; 2014 Jul; 40(1):11-2. PubMed ID: 24990765
[No Abstract] [Full Text] [Related]
7. Gadolinium- or iodine-based contrast media: which choice?
Thomsen HS
Acta Radiol; 2014 Sep; 55(7):771-5. PubMed ID: 25138436
[No Abstract] [Full Text] [Related]
8. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
Thomsen HS
Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
[TBL] [Abstract][Full Text] [Related]
9. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
[No Abstract] [Full Text] [Related]
10. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
van der Molen AJ
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):339-50. PubMed ID: 18811757
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
Wang SC
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
[No Abstract] [Full Text] [Related]
12. Removal of gadolinium by dialysis: review of different strategies and techniques.
Silberzweig JI; Chung M
J Magn Reson Imaging; 2009 Dec; 30(6):1347-9. PubMed ID: 19937933
[TBL] [Abstract][Full Text] [Related]
13. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe.
Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1357-63. PubMed ID: 19937935
[TBL] [Abstract][Full Text] [Related]
14. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
[TBL] [Abstract][Full Text] [Related]
15. Update on nephrogenic systemic fibrosis.
Thomsen HS; Marckmann P; Logager VB
Magn Reson Imaging Clin N Am; 2008 Nov; 16(4):551-60, vii. PubMed ID: 18926421
[TBL] [Abstract][Full Text] [Related]
16. Guideline to use gadolinium-based contrast agents at Kyoto University Hospital.
Miki Y; Isoda H; Togashi K
J Magn Reson Imaging; 2009 Dec; 30(6):1364-5. PubMed ID: 19937936
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid.
Nazarian RM; Mandal RV; Kagan A; Kay J; Duncan LM
J Am Acad Dermatol; 2011 Apr; 64(4):741-7. PubMed ID: 21414498
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update.
Jalandhara N; Arora R; Batuman V
Clin Pharmacol Ther; 2011 Jun; 89(6):920-3. PubMed ID: 21471962
[No Abstract] [Full Text] [Related]
19. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
Varela CU; Prieto-Rayo JC
Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
[TBL] [Abstract][Full Text] [Related]
20. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm.
Perazella MA
Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):519-25. PubMed ID: 19623065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
